Novavax Inc.

NASDAQ: NVAX · Real-Time Price · USD
9.58
0.15 (1.59%)
At close: Aug 15, 2025, 3:59 PM
9.59
0.10%
After-hours: Aug 15, 2025, 06:06 PM EDT

Novavax Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
682.16M 556.38M 1.6B 1.15B
Cost of Revenue
202.74M 343.77M 902.64M 12.66M
Gross Profit
479.42M 212.61M 696.31M 1.13B
Operating Income
-248.93M -566.51M -644.74M -1.69B
Interest Income
n/a n/a 19.88M 1.36M
Pretax Income
-176.62M -543.03M -653.65M -1.71B
Net Income
-187.5M -545.06M -657.94M -1.74B
Selling & General & Admin
337.19M 468.95M 488.69M 298.36M
Research & Development
391.17M 737.5M 1.24B 2.53B
Other Expenses
n/a -427.32M -382.92M -8.2M
Operating Expenses
728.35M 779.13M 1.34B 2.83B
Interest Expense
20.07M 14.42M 19.88M 21.13M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
931.09M 1.12B 2.24B 2.83B
Income Tax Expense
10.88M 2.03M 4.29M 29.21M
Shares Outstanding (Basic)
152.19M 100.77M 78.18M 74.4M
Shares Outstanding (Diluted)
152.19M 100.77M 78.18M 74.4M
EPS (Basic)
-1.23 -5.41 -8.42 -23.44
EPS (Diluted)
-1.23 -5.41 -8.42 -23.44
EBITDA
-108.04M -487.39M -604.71M -1.68B
EBIT
-156.54M -528.62M -633.77M -1.69B
Depreciation & Amortization
48.5M 41.23M 29.05M 12.66M